Van Strum & Towne Inc. Sells 1,790 Shares of Johnson & Johnson $JNJ

Van Strum & Towne Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.8% in the second quarter, HoldingsChannel reports. The firm owned 45,707 shares of the company’s stock after selling 1,790 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Van Strum & Towne Inc.’s holdings, making the stock its 14th largest holding. Van Strum & Towne Inc.’s holdings in Johnson & Johnson were worth $6,982,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Natural Investments LLC grew its position in shares of Johnson & Johnson by 12.6% during the 2nd quarter. Natural Investments LLC now owns 7,342 shares of the company’s stock valued at $1,121,000 after acquiring an additional 823 shares during the period. IRON Financial LLC lifted its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. IRON Financial LLC now owns 10,646 shares of the company’s stock valued at $1,626,000 after buying an additional 68 shares in the last quarter. One Degree Advisors Inc lifted its stake in shares of Johnson & Johnson by 28.1% during the 2nd quarter. One Degree Advisors Inc now owns 1,594 shares of the company’s stock valued at $243,000 after buying an additional 350 shares in the last quarter. Avion Wealth lifted its stake in shares of Johnson & Johnson by 11.1% during the 2nd quarter. Avion Wealth now owns 1,169 shares of the company’s stock valued at $193,000 after buying an additional 117 shares in the last quarter. Finally, Bey Douglas LLC lifted its stake in shares of Johnson & Johnson by 5.4% during the 2nd quarter. Bey Douglas LLC now owns 2,043 shares of the company’s stock valued at $312,000 after buying an additional 104 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $190.88 on Tuesday. The firm’s fifty day moving average price is $178.88 and its 200-day moving average price is $163.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market cap of $459.71 billion, a P/E ratio of 20.42, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $192.94.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.